NA
RPRX icon

NewEdge Advisors’s Royalty Pharma RPRX Stock Holding History

NewEdge Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Buy
21,597
+17,279
+400% +$899K ﹤0.01% 1539
2026
Q1 		$207K Buy
+4,318
New +$189K ﹤0.01% 2585
2023
Q1 		– Sell
-1,649
Closed -$64.9K – 4005
2022
Q4 		$64.9K Buy
+1,649
New +$68.8K ﹤0.01% 1615

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Advisors's RPRX Position: Q2 2026 in Review

NewEdge Advisors increased its Royalty Pharma (RPRX) stake by 400% in Q2 2026, buying an estimated $899K and bringing the position to 21,597 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1539.

NewEdge Advisors first reported a position in RPRX in Q4 2022 and has held it in 3 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • NewEdge Advisors held 21,597 shares of Royalty Pharma worth $1.21M as of Q2 2026.
  • NewEdge Advisors bought 17,279 Royalty Pharma shares in Q2 2026, an estimated $899K.
  • Royalty Pharma made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #1539 holding.
  • NewEdge Advisors first reported a position in Royalty Pharma in Q4 2022 and has held it in 3 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.